JJ777
2021-03-18
good
Moderna's Latest Move May be Key to COVID-19 Vaccine Market Dominance
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
1
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":327806441,"tweetId":"327806441","gmtCreate":1616074792683,"gmtModify":1634527373518,"author":{"id":3575925842692907,"idStr":"3575925842692907","authorId":3575925842692907,"authorIdStr":"3575925842692907","name":"JJ777","avatar":"https://static.tigerbbs.com/01f75dc0b802594bbf8c5c22b48ab435","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":0,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>good</p></body></html>","htmlText":"<html><head></head><body><p>good</p></body></html>","text":"good","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/327806441","repostId":1164556914,"repostType":4,"repost":{"id":"1164556914","kind":"news","pubTimestamp":1616070336,"share":"https://ttm.financial/m/news/1164556914?lang=&edition=full","pubTime":"2021-03-18 20:25","market":"us","language":"en","title":"Moderna's Latest Move May be Key to COVID-19 Vaccine Market Dominance","url":"https://stock-news.laohu8.com/highlight/detail?id=1164556914","media":"Motley Fool","summary":"And it could mean at least another $1 billion in revenue for the biotech.\n\nModerna(NASDAQ:MRNA)may a","content":"<blockquote>\n <b>And it could mean at least another $1 billion in revenue for the biotech.</b>\n</blockquote>\n<p><b>Moderna</b>(NASDAQ:MRNA)may already seem like a market leader. The biotech company's COVID-19 vaccine was only the second to earn an emergency use authorization (EUA) from the Food and Drug Administration, shortly after<b>Pfizer</b>and partner<b>BioNTech</b>garnered one forBNT162b2. In the months since, the U.S. has administered more than 54 million doses of the Moderna vaccine alone. And the Biden administration signed additional deals to buy enough Moderna and Pfizer doses to vaccinate the entire U.S. population.</p>\n<p>But these companies are not yet able to cater to the whole potential market. The FDA has only authorized their vaccines -- and the recently approved<b>Johnson & Johnson</b>inoculation -- for use in adults.</p>\n<p>This week, however, Moderna became the first to launch a COVID-19 vaccine trial in children ages 6 months through 11 years old. And its speed here might give it a sales edge.</p>\n<p><b>The first EUAs</b></p>\n<p>The FDA granted the Moderna and Johnson & Johnson vaccines EUAs for people 18 and older, but authorized Pfizer's vaccine for those 16 and older. That's because Pfizer presented satisfactory trial data on participants in that slightly wider age range.</p>\n<p>Now, Moderna and Pfizer both are already studying their vaccines in teens. Both recently said their teen trials are fully enrolled. Moderna earlier said it's targeting a data readout this spring and vaccine deployment in time for autumn's back-to-school period. We might expect both companies to vie for this market at about the same time. Johnson & Johnson hasn't yet launched trials in the under-18 population. But it plans to do so, according to a<i>USA Today</i>report.</p>\n<p>When it comes to vaccinating an even younger population, it's clear Moderna has taken the lead from a timeline perspective. The biotech expects to vaccinate 6,750 healthy participants in the U.S. and Canada in its phase 2/3 pediatric study. The trial includes two parts. In part one, researchers will give participants ages 2 through 11 one of two possible doses ofmRNA-1273, while those who are younger will receive one of three possible doses. The data gleaned from that phase will determine the dosage to be used in the second part of the trial, which will include a vaccine group and a control group that will receive placebos.</p>\n<p>Moderna has not said how quickly it expects the study to generate results. But if all goes smoothly,mRNA-1273may be available to the pediatric market ahead of rivals. Being first to market almost always confers an advantage. If doctors and their patients are satisfied with the earliest arrival's safety profile and efficacy, they're likely to stick with it.</p>\n<p><b>What does this mean for Moderna's revenue?</b></p>\n<p>Let's do a little math. About 15% of the U.S. population is under 12, according to National Kids Count data. That's more than 48 million individuals. Using the price the federal government paid Moderna for itsmRNA-1273doses and considering a two-dose regimen, we can make a sales estimate. At $15 per dose for about 100 million doses to vaccinate children, Moderna would generate $1.5 billion in revenue in the U.S. market alone. And there's certainly room for it to grow revenue further by meeting the vaccine needs of younger populations in foreign markets.</p>\n<p>Though severe cases of COVID-19 are relatively rare in children, vaccinating the younger set will nonetheless be a key step in stemming the spread of coronavirus and ending the pandemic. It's not entirely clear yet the degree to which vaccination reduces the transmission of the virus by those who become infected despite having been inoculated. But fewer symptomatic infections may reduce viral shedding into the environment, which means fewer people would be exposed to COVID-19.</p>\n<p>Will Moderna be the first company able to vaccinate across all age groups? Clinical trial data will answer that question. But if it doesn't encounter any surprises, Moderna could win this stage of the race, giving it a leg up on its rivals.</p>\n<p>Of course, in this case, issues of supply and demand mean that such dominance can only take a company so far. Moderna's capacity to producemRNA-1273this year is expected to be between 700 million and 1 billion doses. That's not enough to vaccinate the whole world. It will take many companies to complete the task. So Pfizer, Johnson & Johnson, and other vaccine makers all stand to benefit.</p>\n<p>What this clinical trial news does mean is that Moderna investors have one more reason to be optimistic about thebiotech company-- and its abilityto increase its revenueover the long term.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna's Latest Move May be Key to COVID-19 Vaccine Market Dominance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna's Latest Move May be Key to COVID-19 Vaccine Market Dominance\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-18 20:25 GMT+8 <a href=https://www.fool.com/investing/2021/03/18/modernas-latest-move-may-be-key-to-covid-19-vaccin/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>And it could mean at least another $1 billion in revenue for the biotech.\n\nModerna(NASDAQ:MRNA)may already seem like a market leader. The biotech company's COVID-19 vaccine was only the second to earn...</p>\n\n<a href=\"https://www.fool.com/investing/2021/03/18/modernas-latest-move-may-be-key-to-covid-19-vaccin/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/03/18/modernas-latest-move-may-be-key-to-covid-19-vaccin/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164556914","content_text":"And it could mean at least another $1 billion in revenue for the biotech.\n\nModerna(NASDAQ:MRNA)may already seem like a market leader. The biotech company's COVID-19 vaccine was only the second to earn an emergency use authorization (EUA) from the Food and Drug Administration, shortly afterPfizerand partnerBioNTechgarnered one forBNT162b2. In the months since, the U.S. has administered more than 54 million doses of the Moderna vaccine alone. And the Biden administration signed additional deals to buy enough Moderna and Pfizer doses to vaccinate the entire U.S. population.\nBut these companies are not yet able to cater to the whole potential market. The FDA has only authorized their vaccines -- and the recently approvedJohnson & Johnsoninoculation -- for use in adults.\nThis week, however, Moderna became the first to launch a COVID-19 vaccine trial in children ages 6 months through 11 years old. And its speed here might give it a sales edge.\nThe first EUAs\nThe FDA granted the Moderna and Johnson & Johnson vaccines EUAs for people 18 and older, but authorized Pfizer's vaccine for those 16 and older. That's because Pfizer presented satisfactory trial data on participants in that slightly wider age range.\nNow, Moderna and Pfizer both are already studying their vaccines in teens. Both recently said their teen trials are fully enrolled. Moderna earlier said it's targeting a data readout this spring and vaccine deployment in time for autumn's back-to-school period. We might expect both companies to vie for this market at about the same time. Johnson & Johnson hasn't yet launched trials in the under-18 population. But it plans to do so, according to aUSA Todayreport.\nWhen it comes to vaccinating an even younger population, it's clear Moderna has taken the lead from a timeline perspective. The biotech expects to vaccinate 6,750 healthy participants in the U.S. and Canada in its phase 2/3 pediatric study. The trial includes two parts. In part one, researchers will give participants ages 2 through 11 one of two possible doses ofmRNA-1273, while those who are younger will receive one of three possible doses. The data gleaned from that phase will determine the dosage to be used in the second part of the trial, which will include a vaccine group and a control group that will receive placebos.\nModerna has not said how quickly it expects the study to generate results. But if all goes smoothly,mRNA-1273may be available to the pediatric market ahead of rivals. Being first to market almost always confers an advantage. If doctors and their patients are satisfied with the earliest arrival's safety profile and efficacy, they're likely to stick with it.\nWhat does this mean for Moderna's revenue?\nLet's do a little math. About 15% of the U.S. population is under 12, according to National Kids Count data. That's more than 48 million individuals. Using the price the federal government paid Moderna for itsmRNA-1273doses and considering a two-dose regimen, we can make a sales estimate. At $15 per dose for about 100 million doses to vaccinate children, Moderna would generate $1.5 billion in revenue in the U.S. market alone. And there's certainly room for it to grow revenue further by meeting the vaccine needs of younger populations in foreign markets.\nThough severe cases of COVID-19 are relatively rare in children, vaccinating the younger set will nonetheless be a key step in stemming the spread of coronavirus and ending the pandemic. It's not entirely clear yet the degree to which vaccination reduces the transmission of the virus by those who become infected despite having been inoculated. But fewer symptomatic infections may reduce viral shedding into the environment, which means fewer people would be exposed to COVID-19.\nWill Moderna be the first company able to vaccinate across all age groups? Clinical trial data will answer that question. But if it doesn't encounter any surprises, Moderna could win this stage of the race, giving it a leg up on its rivals.\nOf course, in this case, issues of supply and demand mean that such dominance can only take a company so far. Moderna's capacity to producemRNA-1273this year is expected to be between 700 million and 1 billion doses. That's not enough to vaccinate the whole world. It will take many companies to complete the task. So Pfizer, Johnson & Johnson, and other vaccine makers all stand to benefit.\nWhat this clinical trial news does mean is that Moderna investors have one more reason to be optimistic about thebiotech company-- and its abilityto increase its revenueover the long term.","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":270,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/327806441"}
精彩评论